BioCardia, Inc. (NASDAQ:BCDA) Sees Significant Increase in Short Interest

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 109,500 shares, a growth of 26.9% from the October 31st total of 86,300 shares. Based on an average daily volume of 822,600 shares, the short-interest ratio is currently 0.1 days. Approximately 3.1% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of BioCardia in a research report on Thursday, November 14th.

BioCardia Stock Performance

Shares of BCDA traded down $0.07 during trading hours on Friday, reaching $2.28. 16,839 shares of the company traded hands, compared to its average volume of 287,053. The stock’s fifty day moving average is $2.47 and its 200 day moving average is $3.08. The stock has a market cap of $10.44 million, a P/E ratio of -0.54 and a beta of 1.28. BioCardia has a 1-year low of $1.84 and a 1-year high of $10.79.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.